CBDG (THC Farmaceuticals) EBIT: $-0.00 Mil (TTM As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is THC Farmaceuticals EBIT?

THC Farmaceuticals CBDG EBIT is $-0.00 Mil as of Jun. 2018.

THC Farmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2018 was $-0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2018 was $-0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. THC Farmaceuticals's annualized ROC % for the quarter that ended in Jun. 2018 was -0.69%. THC Farmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2018 was -51.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. THC Farmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2018 was -1.68%.

THC Farmaceuticals  (OTCPK:CBDG) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

THC Farmaceuticals's annualized ROC % for the quarter that ended in Jun. 2018 is calculated as:

ROC % (Q: Jun. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2018 ) + Invested Capital (Q: Jun. 2018 ))/ count )
=-0.012 * ( 1 - 0% )/( (1.738 + 1.737)/ 2 )
=-0.012/1.7375
=-0.69 %

where

Invested Capital(Q: Mar. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.752 - 0.012 - ( 0.002 - max(0, 0.012 - 0.65+0.002))
=1.738

Invested Capital(Q: Jun. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.751 - 0.012 - ( 0.002 - max(0, 0.012 - 0.65+0.002))
=1.737

Note: The Operating Income data used here is four times the quarterly (Jun. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

THC Farmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2018 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2018 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2018  Q: Jun. 2018
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.012/( ( (0.01 + max(0.014, 0)) + (0.009 + max(0.014, 0)) )/ 2 )
=-0.012/( ( 0.024 + 0.023 )/ 2 )
=-0.012/0.0235
=-51.06 %

where Working Capital is:

Working Capital(Q: Mar. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0 + 0.025) - (0.012 + 0 + 0)
=0.014

Working Capital(Q: Jun. 2018 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.001 + 0 + 0.025) - (0.012 + 0 + 0)
=0.014

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

THC Farmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2018 )
=-0.004/0.238
=-1.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THC Farmaceuticals EBIT Related Terms

THC Farmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for THC Farmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THC Farmaceuticals EBIT Chart

THC Farmaceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13
EBIT
-0.00 -0.02 -0.04 -0.02

THC Farmaceuticals Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Mar17 Jun17 Mar18 Jun18
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.00 -0.00 -0.00 -0.00

CBDG vs BOXS: EBIT Comparison

For the Biotechnology subindustry, THC Farmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

THC Farmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, THC Farmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where THC Farmaceuticals's EV-to-EBIT falls into.


THC Farmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.00 Mil mean?
THC Farmaceuticals (CBDG) has a EBIT of $-0.00 Mil as of Jun. 2018. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on THC Farmaceuticals.
Is THC Farmaceuticals' EBIT too high?
THC Farmaceuticals' current EBIT is $-0.00 Mil.
How does THC Farmaceuticals' EBIT compare to BOXS?
THC Farmaceuticals' EBIT of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on THC Farmaceuticals. THC Farmaceuticals's current EBIT is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THC Farmaceuticals stock overvalued right now?
THC Farmaceuticals (CBDG) has a current EBIT of $-0.00 Mil. The current EBIT is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For THC Farmaceuticals (CBDG), the current EBIT is $-0.00 Mil as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THC Farmaceuticals Business Description

Address 2789 Rio Vista Drive, Suite 3, Saint George, UT, USA, 84790
THC Farmaceuticals Inc is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology, and other medical disciplines. It offers the combination of proprietary developments with the expertise of clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds.